{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:50Z","timestamp":1791912470699,"version":"4.3.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00415-026-13778-1","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T10:45:05Z","timestamp":1775126705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0638-6779","authenticated-orcid":false,"given":"Eugenia","family":"Filippakopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriilaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianthi","family":"Arnaoutoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Kimiskidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Di Giovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"13778_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A et al (2019) Myasthenia gravis Nat Rev Dis Primers 5:30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Myasthenia gravis Nat Rev Dis Primers"},{"key":"13778_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/nyas.13592","volume":"1413","author":"A Vincent","year":"2018","unstructured":"Vincent A, Huda S, Cao M et al (2018) Serological and experimental studies in different forms of myasthenia gravis. Ann N Y Acad Sci 1413:143\u2013153. https:\/\/doi.org\/10.1111\/nyas.13592","journal-title":"Ann N Y Acad Sci"},{"key":"13778_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/08916930903518107","volume":"43","author":"DB Sanders","year":"2010","unstructured":"Sanders DB, Evoli A (2010) Immunosuppressive therapies in myasthenia gravis. Autoimmunity 43:428\u2013435. https:\/\/doi.org\/10.3109\/08916930903518107","journal-title":"Autoimmunity"},{"key":"13778_CR4","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:1756285617749134. https:\/\/doi.org\/10.1177\/1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"key":"13778_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","volume":"14","author":"H Murai","year":"2023","unstructured":"Murai H, Utsugisawa K, Motomura M et al (2023) The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome. Clin Exp Neuroimmunol 14:19\u201327. https:\/\/doi.org\/10.1111\/cen3.12739","journal-title":"Clin Exp Neuroimmunol"},{"key":"13778_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","volume":"18","author":"MC Dalakas","year":"2022","unstructured":"Dalakas MC (2022) Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol 18:691\u2013701. https:\/\/doi.org\/10.1080\/1744666X.2022.2082946","journal-title":"Expert Rev Clin Immunol"},{"key":"13778_CR7","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"key":"13778_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M et al (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60:14\u201324. https:\/\/doi.org\/10.1002\/mus.26447","journal-title":"Muscle Nerve"},{"key":"13778_CR9","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","volume":"270","author":"A Meisel","year":"2023","unstructured":"Meisel A, Annane D, Vu T et al (2023) Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol 270:3862\u20133875. https:\/\/doi.org\/10.1007\/s00415-023-11699-x","journal-title":"J Neurol"},{"key":"13778_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr, Bresch S, Genge A et al (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22:395\u2013406. https:\/\/doi.org\/10.1016\/S1474-4422(23)00080","journal-title":"Lancet Neurol"},{"key":"13778_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241243186","volume":"17","author":"JF Howard Jr","year":"2024","unstructured":"Howard JF Jr, Bresch S, Farmakidis C et al (2024) Long-term safety and efficacy of zilucoplan in patients with generalized Myasthenia gravis: interim analysis of the RAISE-XT open-label extension study. Ther Adv Neurol Disord 17:17562864241243186. https:\/\/doi.org\/10.1177\/17562864241243186","journal-title":"Ther Adv Neurol Disord"},{"issue":"18","key":"13778_CR12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1212\/WNL.98.18_supplement.791","volume":"98","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R et al (2022) Efficacy and safety of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG study. Neurology 98(18):791","journal-title":"Neurology"},{"issue":"15","key":"13778_CR13","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1212\/WNL.96.15_supplement.4520","volume":"96","author":"J Howard","year":"2021","unstructured":"Howard J, Bril V, Vu T et al (2021) Efficacy, safety, and tolerability of efgartigimod in patients with generalized myasthenia gravis: analysis of the phase 3 ADAPT study. Neurology 96(15):4520","journal-title":"Neurology"},{"key":"13778_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J et al (2023) Safety and efficacy of rozanolixizumab in patients with generalised Myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive Phase 3 study. Lancet Neurol 22:383\u2013394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077","journal-title":"Lancet Neurol"},{"key":"13778_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","volume":"81","author":"C Yan","year":"2024","unstructured":"Yan C, Yue Y, Guan Y et al (2024) Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial. JAMA Neurol 81:336\u2013345. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0044","journal-title":"JAMA Neurol"},{"key":"13778_CR16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A et al (2022) Efficacy and safety of rituximab for new-onset generalized Myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol 79:1105\u20131112. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"key":"13778_CR17","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","volume":"392","author":"RJ Nowak","year":"2025","unstructured":"Nowak RJ, Benatar M, Ciafaloni E et al (2025) A Phase 3 trial of inebilizumab in generalized Myasthenia gravis. N Engl J Med 392:2309\u20132320. https:\/\/doi.org\/10.1056\/NEJMoa2501561","journal-title":"N Engl J Med"},{"key":"13778_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16322","volume":"31","author":"J Yin","year":"2024","unstructured":"Yin J, Zhao M, Xu X et al (2024) A multicenter, randomized, open-label, Phase 2 clinical study of telitacicept in adult patients with generalized Myasthenia gravis. Eur J Neurol 31:e16322. https:\/\/doi.org\/10.1111\/ene.16322","journal-title":"Eur J Neurol"},{"key":"13778_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-12922-7","volume":"272","author":"SNM Binks","year":"2025","unstructured":"Binks SNM, Morse IM, Ashraghi M et al (2025) Myasthenia gravis in 2025: five new things and four hopes for the future. J Neurol 272:226. https:\/\/doi.org\/10.1007\/s00415-025-12922-7","journal-title":"J Neurol"},{"key":"13778_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000211115","volume":"104","author":"C Antozzi","year":"2025","unstructured":"Antozzi C, Vu T, Ramchandren S et al (2025) Long-term safety and efficacy of nipocalimab in generalized myasthenia gravis: Vivacity-MG3 open-label extension phase results (P7-11.022). Neurology 104:3608. https:\/\/doi.org\/10.1212\/WNL.0000000000211115","journal-title":"Neurology"},{"key":"13778_CR21","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1007\/s12325-024-03014-5","volume":"41","author":"AG Smith","year":"2024","unstructured":"Smith AG, Wolfe GI, Habib AA et al (2024) Risk\u2013benefit analysis of novel treatments for patients with generalized Myasthenia gravis. Adv Ther 41:4628\u20134647. https:\/\/doi.org\/10.1007\/s12325-024-03014-5","journal-title":"Adv Ther"},{"key":"13778_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International consensus guidance for management of Myasthenia gravis: 2020 update. Neurology 96:114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"13778_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16229","volume":"31","author":"NE Gilhus","year":"2024","unstructured":"Gilhus NE, Andersen H, Andersen LK et al (2024) Generalized Myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment. Eur J Neurol 31:e16229. https:\/\/doi.org\/10.1111\/ene.16229","journal-title":"Eur J Neurol"},{"key":"13778_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"13778_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"13778_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"13778_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926","journal-title":"BMJ"},{"key":"13778_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-9-80","volume":"9","author":"BC Wallace","year":"2009","unstructured":"Wallace BC, Schmid CH, Lau J, Trikalinos TA (2009) Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 9:80. https:\/\/doi.org\/10.1186\/1471-2288-9-80","journal-title":"BMC Med Res Methodol"},{"key":"13778_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557","journal-title":"BMJ"},{"key":"13778_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"13778_CR31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/acn3.51946","volume":"11","author":"RJ Nowak","year":"2024","unstructured":"Nowak RJ, Breiner A, Bril V et al (2024) Subcutaneous batoclimab in generalized myasthenia gravis: results from a phase 2a trial with an open-label extension. Ann Clin Transl Neurol 11:194\u2013206. https:\/\/doi.org\/10.1002\/acn3.51946","journal-title":"Ann Clin Transl Neurol"},{"key":"13778_CR32","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","volume":"270","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Barnett C, Vu T et al (2023) Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT). J Neurol 270:2096\u20132105","journal-title":"J Neurol"},{"key":"13778_CR33","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","volume":"28","author":"H Andersen","year":"2019","unstructured":"Andersen H, Mantegazza R, Wang JJ et al (2019) Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res 28:2247\u20132254. https:\/\/doi.org\/10.1007\/s11136-019-02148-2","journal-title":"Qual Life Res"},{"key":"13778_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12209-3","author":"MD Weiss","year":"2024","unstructured":"Weiss MD, Freimer M, Leite MI et al (2024) Improvement of fatigue in generalised myasthenia gravis with zilucoplan. J Neurol. https:\/\/doi.org\/10.1007\/s00415-024-12209-3","journal-title":"J Neurol"},{"key":"13778_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123264","volume":"466","author":"S Dewilde","year":"2024","unstructured":"Dewilde S, Qi CZ, Phillips G et al (2024) Post hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of efgartigimod in generalized myasthenia gravis. J Neurol Sci 466:123264","journal-title":"J Neurol Sci"},{"key":"13778_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1284444","volume":"14","author":"JF Howard","year":"2024","unstructured":"Howard JF, Bril V, Vu T et al (2024) Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis. Front Neurol 14:2023","journal-title":"Front Neurol"},{"key":"13778_CR37","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1017\/cjn.2024.164","volume":"51","author":"V Bril","year":"2024","unstructured":"Bril V, Howard JF, Murai H et al (2024) Achievement of minimal symptom expression in acetylcholine receptor antibody-positive participants treated with efgartigimod in ADAPT\/ADAPT+. Can J Neurol Sci 51:S31\u2013S31","journal-title":"Can J Neurol Sci"},{"key":"13778_CR38","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","volume":"267","author":"J Vissing","year":"2020","unstructured":"Vissing J, Jacob S, Fujita KP et al (2020) \u201cMinimal symptom expression\u201d in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol 267:1991\u20132001","journal-title":"J Neurol"},{"key":"13778_CR39","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","volume":"96","author":"R Mantegazza","year":"2021","unstructured":"Mantegazza R, Wolfe GI, Muppidi S et al (2021) Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension. Neurology 96:e610\u2013e618. https:\/\/doi.org\/10.1212\/WNL.0000000000011207","journal-title":"Neurology"},{"issue":"17","key":"13778_CR40","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1212\/WNL.0000000000202156","volume":"100","author":"S Muppidi","year":"2023","unstructured":"Muppidi S, Narayanaswami P, Meisel A et al (2023) Achievement of improved post-intervention status in patients with generalized myasthenia gravis treated with ravulizumab during the CHAMPION MG study. Neurology 100(17):1852. https:\/\/doi.org\/10.1212\/WNL.0000000000202156","journal-title":"Neurology"},{"key":"13778_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.556104","volume":"11","author":"RJ Nowak","year":"2020","unstructured":"Nowak RJ, Muppidi S, Beydoun SR et al (2020) Concomitant immunosuppressive therapy use in eculizumab-treated adults with generalized myasthenia gravis during the REGAIN open-label extension study. Front Neurol 11:556104","journal-title":"Front Neurol"},{"key":"13778_CR42","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1017\/cjn.2024.160","volume":"51","author":"M Nicolle","year":"2024","unstructured":"Nicolle M, Annane D, Meisel A et al (2024) Concomitant corticosteroid use in ravulizumab-treated adults with anti-AChR antibody-positive gMG: results from the CHAMPION MG open-label extension. Can J Neurol Sci 51:S30\u2013S30. https:\/\/doi.org\/10.1017\/cjn.2024.160","journal-title":"Can J Neurol Sci"},{"key":"13778_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.121094","volume":"455","author":"Z Siddiqi","year":"2023","unstructured":"Siddiqi Z, Rozsa C, Sacc\u00e0 F et al (2023) Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis regardless of prior treatment failures. J Neurol Sci 455:121094. https:\/\/doi.org\/10.1016\/j.jns.2023.121094","journal-title":"J Neurol Sci"},{"key":"13778_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.121883","volume":"455","author":"S Fam","year":"2023","unstructured":"Fam S, Werneburg B, Pandya S et al (2023) Clinical and real-world pharmacovigilance data of meningococcal infections in eculizumab- or ravulizumab-treated patients. J Neurol Sci 455:121883. https:\/\/doi.org\/10.1016\/j.jns.2023.121883","journal-title":"J Neurol Sci"},{"key":"13778_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16280","volume":"31","author":"A Meisel","year":"2024","unstructured":"Meisel A, Sacc\u00e0 F, Spillane J, Vissing J (2024) Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis. Eur J Neurol 31:e16280. https:\/\/doi.org\/10.1111\/ene.16280","journal-title":"Eur J Neurol"},{"key":"13778_CR46","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s40120-024-00667-w","volume":"13","author":"JL Petrie","year":"2024","unstructured":"Petrie JL, Smith CA, Fountain D, Machnicki G (2024) Real-world persistence with ocrelizumab in multiple sclerosis: a systematic review. Neurol Ther 13:1597\u20131605. https:\/\/doi.org\/10.1007\/s40120-024-00667-w","journal-title":"Neurol Ther"},{"key":"13778_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.790834","volume":"12","author":"Z Song","year":"2022","unstructured":"Song Z, Zhang J, Meng J et al (2022) Different monoclonal antibodies in myasthenia gravis: a Bayesian network meta-analysis. Front Pharmacol 12:2021","journal-title":"Front Pharmacol"},{"key":"13778_CR48","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE et al (2023) Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol 30:3854\u20133867. https:\/\/doi.org\/10.1111\/ene.15872","journal-title":"Eur J Neurol"},{"key":"13778_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","volume":"38","author":"Y Ma","year":"2024","unstructured":"Ma Y, Nie X, Zhu G et al (2024) The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and Bayesian network meta-analysis. CNS Drugs 38:93\u2013104. https:\/\/doi.org\/10.1007\/s40263-024-01062-7","journal-title":"CNS Drugs"},{"key":"13778_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05751-1","volume":"22","author":"J Gu","year":"2024","unstructured":"Gu J, Qiao Y, Huang R, Cong S (2024) Efficacy and safety of immunosuppressants and monoclonal antibodies in adults with myasthenia gravis: a systematic review and network meta-analysis. J Transl Med 22:955. https:\/\/doi.org\/10.1186\/s12967-024-05751-1","journal-title":"J Transl Med"},{"key":"13778_CR51","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","volume":"271","author":"J Li","year":"2024","unstructured":"Li J, Wu X, Chu T et al (2024) The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis. J Neurol 271:2298\u20132308. https:\/\/doi.org\/10.1007\/s00415-024-12247-x","journal-title":"J Neurol"},{"key":"13778_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1479685","volume":"15","author":"H Zhong","year":"2024","unstructured":"Zhong H, Li Z, Li X et al (2024) Initiation response, maximized therapeutic efficacy, and post-treatment effects of biological targeted therapies in myasthenia gravis: a systematic review and network meta-analysis. Front Neurol 15:2024","journal-title":"Front Neurol"},{"key":"13778_CR53","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s12325-024-02856-3","volume":"41","author":"C van Steen","year":"2024","unstructured":"van Steen C, Celico L, Spaepen E et al (2024) Efgartigimod and ravulizumab for treating acetylcholine receptor autoantibody-positive generalized myasthenia gravis: indirect treatment comparison. Adv Ther 41:2486\u20132499. https:\/\/doi.org\/10.1007\/s12325-024-02856-3","journal-title":"Adv Ther"},{"key":"13778_CR54","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","volume":"98","author":"RJ Nowak","year":"2022","unstructured":"Nowak RJ, Coffey CS, Goldstein JM et al (2022) Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology 98:e376\u2013e389. https:\/\/doi.org\/10.1212\/WNL.0000000000013121","journal-title":"Neurology"},{"key":"13778_CR55","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","volume":"77","author":"S Brauner","year":"2020","unstructured":"Brauner S, Eriksson-Dufva A, Hietala MA et al (2020) Comparison between Rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol 77:974\u2013981. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0851","journal-title":"JAMA Neurol"},{"key":"13778_CR56","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D et al (2023) Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol 22:1104\u20131105. https:\/\/doi.org\/10.1016\/S1474-4422(23)00375-7","journal-title":"Lancet Neurol"},{"key":"13778_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2025.109011","volume":"256","author":"E Rossini","year":"2025","unstructured":"Rossini E, Morino S, Garibaldi M et al (2025) Emergent role of complement inhibitors in myasthenic crisis: understanding why, when and how. Clin Neurol Neurosurg 256:109011. https:\/\/doi.org\/10.1016\/j.clineuro.2025.109011","journal-title":"Clin Neurol Neurosurg"},{"key":"13778_CR58","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.80203","volume":"17","author":"S Ito","year":"2025","unstructured":"Ito S, Sugimoto T, Naito H et al (2025) Zilucoplan for successful early weaning from mechanical ventilation and avoiding tracheostomy in an 85-year-old woman experiencing myasthenic crisis: a case report. Cureus 17:e80203. https:\/\/doi.org\/10.7759\/cureus.80203","journal-title":"Cureus"},{"issue":"10","key":"13778_CR59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/neurolint17100163","volume":"17","author":"S Takahashi","year":"2025","unstructured":"Takahashi S, Kinno R (2025) Management of myasthenic crisis and emerging roles of molecularly targeted therapies: a narrative review. Neurol Int 17(10):163. https:\/\/doi.org\/10.3390\/neurolint17100163","journal-title":"Neurol Int"},{"key":"13778_CR60","doi-asserted-by":"publisher","first-page":"8287","DOI":"10.1007\/s00210-025-03954-x","volume":"398","author":"P Tang","year":"2025","unstructured":"Tang P, He Y, Xiao K, Wang L (2025) A systematic review of Efgartigimod as an effective treatment for myasthenic crisis. Naunyn Schmiedebergs Arch Pharmacol 398:8287\u20138294. https:\/\/doi.org\/10.1007\/s00210-025-03954-x","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"13778_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00730","volume":"22","author":"R Guo","year":"2025","unstructured":"Guo R, Sun C, Huang X et al (2025) Efficacy and safety of Efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: a retrospective cohort study. Neurotherapeutics 22:e00730. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00730","journal-title":"Neurotherapeutics"},{"key":"13778_CR62","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/22143602241305511","volume":"12","author":"V Bril","year":"2025","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J et al (2025) Rozanolixizumab in generalized myasthenia gravis: pooled analysis of the phase 3 MycarinG study and two open-label extensions. J Neuromuscul Dis 12:218\u2013230. https:\/\/doi.org\/10.1177\/22143602241305511","journal-title":"J Neuromuscul Dis"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13778-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13778-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13778-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T01:48:49Z","timestamp":1776649729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13778-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["13778"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13778-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing to declare\n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"244"}}